COVID-19 Virus Statement

23 March 2020

Due to the current impact of the COVID-19 (SARS-CoV-2) virus situation globally, we are continuing to monitor the effect this may have on our business worldwide.

Vitalograph’s manufacturing site is based in Ireland, but as a multinational company with a complex supply chain, we source a few parts in China. Similar to the majority of global companies, our ability to supply product could be affected due to restrictions in China. In the last three weeks parts have begun to flow from China and our sub-suppliers are back to full production capacity. We anticipate little, or no, disruption to our incoming supply chain.

As a global company, we have warehouses in multiple countries holding adequate levels of stock to meet current customer needs. We also have a wide range of products allowing a supply of alternative items should short term stock issues arise. We are seeing a manageable slowing of 2-3 days on outgoing logistics in Europe.

This week there has been further travel restrictions imposed in Europe and we expect further measures to be imposed across Europe and the US. We are prepared for this and invoked Business Continuity Plan (BCP) measures at all sites in the middle of February, including remote working, staggered breaks and dispersed workforce. We practice a robust BCP process, aligned to ISO 22301, tested regularly at all sites.

Our Company Mission is “To improve patient lives through supporting our customers and partners by designing and manufacturing market leading products and services”. This is a mission we take very seriously and our employees live and breathe it on a daily basis. Due to the respiratory effects of COVID-19 we are doubling our efforts to ensure we can fulfill our mission and help those in most need at this time.


Frank Keane CEO